BIOTECH, STOCKS, TECHNOLOGY

John McCamant

Editor,

Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

Celldex (CLDX) recently reported interim data from their ongoing, open label clinical trial of CDX-0159; we believe the severe sell-off following this report was an overreaction, suggests John McCamant, editor of The Medical Technology Stock Letter.
Ziopharm Oncology (ZIOP) recently held an R&D Day to provide an outlook for the company’s future with the new management team in place, notes John McCamant, a biotech sector specialist and editor of The Medical Technology Stock Letter.
Five Prime (FPRX) follows Pharmacyclics, Medicines Company and Celgene, as stocks in The Medical Technology Stock Letter portfolio to be acquired in recent years. Here, editor John McCamant looks at 2 other stocks in his model portfolio that he feels could eventually join this list.
Nektar Therapeutics (NKTR) announced that it has signed two deals to advance BEMPEG combos — one with Merck (MRK) and the other with SFJ Pharmaceuticals, explains John McCamant, biotech expert and editor of The Medical Technology Stock Letter.

John's Videos

Biotech is providing innovative drugs and vaccines for Covod-19. Join John McCamant of the Medical Technology Stock Letter to help you identify the winners.
John McCamant, editor of The Medical Technology Stock Letter, is known for helping investors pick biotech winners. Join this session to discover a unique investment opportunity in a repurposed Phase II pill, poised to treat Covid-19 by reducing viral load.
Biotech is providing innovative drugs and vaccines for Covod-19. Join John McCamant of the Medical Technology Stock Letter to help you identify the winners.
Join John McCamant, editor of the Medical Technology Stock Letter, to discover how from vaccines to new drugs, Covid-19 shines the spotlight biotech's ability to provide solutions.


Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More
Live Now

Money, Metals, & Mining Virtual Expo

April 20 - 22, 2021